Compass Therapeutics, Inc. (CMPX)
CMPX Stock Price Chart
Explore Compass Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CMPX price movements and trends.
CMPX Company Profile
Discover essential business fundamentals and corporate details for Compass Therapeutics, Inc. (CMPX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Apr 2021
Employees
35.00
CEO
Thomas J. Schuetz
Description
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
CMPX Financial Timeline
Browse a chronological timeline of Compass Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.10, while revenue estimate is -$600.00k.
Earnings released on 5 May 2026
EPS came in at -$0.10 matching the estimated -$0.10.
Earnings released on 5 Mar 2026
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%.
Earnings released on 5 Nov 2025
EPS came in at -$0.08 surpassing the estimated -$0.14 by +42.86%.
Earnings released on 11 Aug 2025
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%.
Earnings released on 8 May 2025
EPS came in at -$0.12 matching the estimated -$0.12.
Earnings released on 27 Feb 2025
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%.
Earnings released on 12 Aug 2024
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $850.00k .
Earnings released on 13 May 2024
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%.
Earnings released on 21 Mar 2024
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $2.84m .
Earnings released on 9 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%.
Earnings released on 3 Aug 2023
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%.
Earnings released on 4 May 2023
EPS came in at -$0.06 surpassing the estimated -$0.11 by +45.45%.
Earnings released on 15 Mar 2023
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%.
Earnings released on 9 Nov 2022
EPS came in at -$0.12 falling short of the estimated -$0.11 by -9.09%.
Earnings released on 1 Aug 2022
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.
Earnings released on 9 May 2022
EPS came in at -$0.07 surpassing the estimated -$0.14 by +50.00%.
Earnings released on 21 Mar 2022
EPS came in at -$0.15 falling short of the estimated -$0.07 by -114.29%.
Earnings released on 12 Nov 2021
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%.
Earnings released on 16 Aug 2021
EPS came in at -$1.07 .
CMPX Stock Performance
Access detailed CMPX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
